{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T11:23:14Z","timestamp":1744975394711},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s40263-015-0256-9","type":"journal-article","created":{"date-parts":[[2015,7,18]],"date-time":"2015-07-18T05:29:45Z","timestamp":1437197385000},"page":"519-528","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prevention Studies in Alzheimer\u2019s Disease: Progress Towards the Development of New Therapeutics"],"prefix":"10.1007","volume":"29","author":[{"given":"Nicola","family":"Coley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeline","family":"Gallini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Andrieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,19]]},"reference":[{"key":"256_CR1","doi-asserted-by":"crossref","unstructured":"Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63\u201375 e2.","DOI":"10.1016\/j.jalz.2012.11.007"},{"issue":"9902","key":"256_CR2","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(13)61570-6","volume":"382","author":"FE Matthews","year":"2013","unstructured":"Matthews FE, Arthur A, Barnes LE, Bond J, Jagger C, Robinson L, et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet. 2013;382(9902):1405\u201312.","journal-title":"Lancet."},{"issue":"19","key":"256_CR3","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1212\/WNL.0b013e3182553be6","volume":"78","author":"EM Schrijvers","year":"2012","unstructured":"Schrijvers EM, Verhaaren BF, Koudstaal PJ, Hofman A, Ikram MA, Breteler MM. Is dementia incidence declining? Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology. 2012;78(19):1456\u201363.","journal-title":"Neurology."},{"issue":"1","key":"256_CR4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13195-015-0118-1","volume":"7","author":"KM Langa","year":"2015","unstructured":"Langa KM. Is the risk of Alzheimer\u2019s disease and dementia declining? Alzheimers Res Ther. 2015;7(1):34.","journal-title":"Alzheimers Res Ther."},{"key":"256_CR5","doi-asserted-by":"crossref","unstructured":"Wimo A, Jonsson L, Bond J, Prince M, Winblad B. The worldwide economic impact of dementia 2010. Alzheimers Dement. 2013;9(1):1\u201311 e3.","DOI":"10.1016\/j.jalz.2012.11.006"},{"issue":"4","key":"256_CR6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMra0909142","volume":"362","author":"HW Querfurth","year":"2010","unstructured":"Querfurth HW, LaFerla FM. Alzheimer\u2019s disease. N Engl J Med. 2010;362(4):329\u201344.","journal-title":"N Engl J Med."},{"issue":"7","key":"256_CR7","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","volume":"9","author":"F Mangialasche","year":"2010","unstructured":"Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer\u2019s disease: clinical trials and drug development. Lancet Neurol. 2010;9(7):702\u201316.","journal-title":"Lancet Neurol."},{"issue":"2","key":"256_CR8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ana.24188","volume":"76","author":"E Karran","year":"2014","unstructured":"Karran E, Hardy J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol. 2014;76(2):185\u2013205.","journal-title":"Ann Neurol."},{"issue":"8","key":"256_CR9","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1358\/dnp.2010.23.8.1500435","volume":"23","author":"I Bezprozvanny","year":"2010","unstructured":"Bezprozvanny I. The rise and fall of Dimebon. Drug News Perspect. 2010;23(8):518\u201323.","journal-title":"Drug News Perspect."},{"issue":"4","key":"256_CR10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s12603-009-0045-6","volume":"13","author":"P Douillet","year":"2009","unstructured":"Douillet P, Orgogozo JM. What we have learned from the Xaliproden Sanofi-Aventis trials. J Nutr Health Aging. 2009;13(4):365\u20136.","journal-title":"J Nutr Health Aging."},{"issue":"12","key":"256_CR11","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","volume":"74","author":"HH Feldman","year":"2010","unstructured":"Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010;74(12):956\u201364.","journal-title":"Neurology."},{"issue":"6","key":"256_CR12","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1212\/WNL.0b013e318228bf11","volume":"77","author":"M Sano","year":"2011","unstructured":"Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 2011;77(6):556\u201363.","journal-title":"Neurology."},{"key":"256_CR13","doi-asserted-by":"crossref","unstructured":"Herrup K, Carrillo MC, Schenk D, Cacace A, Desanti S, Fremeau R et al. Beyond amyloid: getting real about nonamyloid targets in Alzheimer\u2019s disease. Alzheimers Dement. 2013;9(4):452\u20138 e1.","DOI":"10.1016\/j.jalz.2013.01.017"},{"issue":"15","key":"256_CR14","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1056\/NEJMc1402193","volume":"370","author":"C Laske","year":"2014","unstructured":"Laske C. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer\u2019s disease. N Engl J Med. 2014;370(15):1459.","journal-title":"N Engl J Med."},{"key":"256_CR15","first-page":"135","volume":"2","author":"GP Morris","year":"2014","unstructured":"Morris GP, Clark IA, Vissel B. Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer\u2019s disease. Acta Neuropathol Commun. 2014;2:135.","journal-title":"Acta Neuropathol Commun."},{"issue":"5","key":"256_CR16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.tips.2013.03.002","volume":"34","author":"F Hefti","year":"2013","unstructured":"Hefti F, Goure WF, Jerecic J, Iverson KS, Walicke PA, Krafft GA. The case for soluble Abeta oligomers as a drug target in Alzheimer\u2019s disease. Trends Pharmacol Sci. 2013;34(5):261\u20136.","journal-title":"Trends Pharmacol Sci."},{"issue":"4","key":"256_CR17","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370(4):322\u201333.","journal-title":"N Engl J Med."},{"issue":"3","key":"256_CR18","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/joim.12192","volume":"275","author":"J Hardy","year":"2014","unstructured":"Hardy J, Bogdanovic N, Winblad B, Portelius E, Andreasen N, Cedazo-Minguez A, et al. Pathways to Alzheimer\u2019s disease. J Intern Med. 2014;275(3):296\u2013303.","journal-title":"J Intern Med."},{"key":"256_CR19","doi-asserted-by":"crossref","unstructured":"Sperling RA, Jack CR, Jr., Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3(111):111cm33.","DOI":"10.1126\/scitranslmed.3002609"},{"issue":"16","key":"256_CR20","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1212\/01.wnl.0000295996.54210.69","volume":"69","author":"JL Cummings","year":"2007","unstructured":"Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology. 2007;69(16):1622\u201334.","journal-title":"Neurology."},{"issue":"7414","key":"256_CR21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/489013a","volume":"489","author":"E Callaway","year":"2012","unstructured":"Callaway E. Alzheimer\u2019s drugs take a new tack. Nature. 2012;489(7414):13\u20134.","journal-title":"Nature."},{"issue":"4","key":"256_CR22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370(4):311\u201321.","journal-title":"N Engl J Med."},{"issue":"2","key":"256_CR23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207\u201316.","journal-title":"Lancet Neurol."},{"issue":"3","key":"256_CR24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.7326\/0003-4819-153-3-201008030-00260","volume":"153","author":"ML Daviglus","year":"2010","unstructured":"Daviglus ML, Bell CC, Berrettini W, Bowen PE, Connolly ES Jr, Cox NJ, et al. National Institutes of Health State-of-the-Science Conference statement: preventing Alzheimer disease and cognitive decline. Ann Intern Med. 2010;153(3):176\u201381.","journal-title":"Ann Intern Med."},{"issue":"3","key":"256_CR25","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","volume":"3","author":"R Brookmeyer","year":"2007","unstructured":"Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer\u2019s disease. Alzheimers Dement. 2007;3(3):186\u201391.","journal-title":"Alzheimers Dement."},{"key":"256_CR26","first-page":"1","volume":"193","author":"JW Williams","year":"2010","unstructured":"Williams JW, Plassman BL, Burke J, Benjamin S. Preventing Alzheimer\u2019s disease and cognitive decline. Evid Rep Technol Assess (Full Rep). 2010;193:1\u2013727.","journal-title":"Evid Rep Technol Assess (Full Rep)."},{"issue":"18","key":"256_CR27","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/01.wnl.0000344650.95823.03","volume":"72","author":"RS Doody","year":"2009","unstructured":"Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology. 2009;72(18):1555\u201361.","journal-title":"Neurology."},{"issue":"23","key":"256_CR28","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa050151","volume":"352","author":"RC Petersen","year":"2005","unstructured":"Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379\u201388.","journal-title":"N Engl J Med."},{"issue":"4","key":"256_CR29","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1212\/01.WNL.0000134664.80320.92","volume":"63","author":"S Salloway","year":"2004","unstructured":"Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology. 2004;63(4):651\u20137.","journal-title":"Neurology."},{"issue":"6","key":"256_CR30","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1474-4422(07)70109-6","volume":"6","author":"HH Feldman","year":"2007","unstructured":"Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer\u2019s disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 2007;6(6):501\u201312.","journal-title":"Lancet Neurol."},{"issue":"6","key":"256_CR31","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s12603-012-0062-8","volume":"16","author":"O Peters","year":"2012","unstructured":"Peters O, Lorenz D, Fesche A, Schmidtke K, Hull M, Perneczky R, et al. A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. J Nutr Health Aging. 2012;16(6):544\u20138.","journal-title":"J Nutr Health Aging."},{"issue":"22","key":"256_CR32","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1212\/01.wnl.0000303815.69777.26","volume":"70","author":"B Winblad","year":"2008","unstructured":"Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology. 2008;70(22):2024\u201335.","journal-title":"Neurology."},{"key":"256_CR33","doi-asserted-by":"crossref","unstructured":"Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6(228):228fs13.","DOI":"10.1126\/scitranslmed.3007941"},{"issue":"10","key":"256_CR34","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.neurol.2013.07.017","volume":"169","author":"SM Mills","year":"2013","unstructured":"Mills SM, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris). 2013;169(10):737\u201343.","journal-title":"Rev Neurol (Paris)."},{"issue":"7","key":"256_CR35","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s00125-012-2538-9","volume":"55","author":"A Neumann","year":"2012","unstructured":"Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 2012;55(7):1953\u201362.","journal-title":"Diabetologia."},{"issue":"2","key":"256_CR36","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40263-015-0230-6","volume":"29","author":"L Rouch","year":"2015","unstructured":"Rouch L, Cestac P, Hanon O, Cool C, Helmer C, Bouhanick B, et al. Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. CNS Drugs. 2015;29(2):113\u201330.","journal-title":"CNS Drugs."},{"issue":"5","key":"256_CR37","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/archneur.63.5.noc60013","volume":"63","author":"AS Khachaturian","year":"2006","unstructured":"Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol. 2006;63(5):686\u201392.","journal-title":"Arch Neurol."},{"key":"256_CR38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/epirev\/mxt008","volume":"36","author":"J O\u2019Brien","year":"2014","unstructured":"O\u2019Brien J, Jackson JW, Grodstein F, Blacker D, Weuve J. Postmenopausal hormone therapy is not associated with risk of all-cause dementia and Alzheimer\u2019s disease. Epidemiol Rev. 2014;36:83\u2013103.","journal-title":"Epidemiol Rev."},{"issue":"17","key":"256_CR39","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1001\/jama.288.17.2123","volume":"288","author":"PP Zandi","year":"2002","unstructured":"Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA. 2002;288(17):2123\u20139.","journal-title":"JAMA."},{"issue":"4","key":"256_CR40","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000078501","volume":"23","author":"CA Szekely","year":"2004","unstructured":"Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, Breitner JC, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer\u2019s disease: a systematic review. Neuroepidemiology. 2004;23(4):159\u201369.","journal-title":"Neuroepidemiology."},{"issue":"7407","key":"256_CR41","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/bmj.327.7407.128","volume":"327","author":"M Etminan","year":"2003","unstructured":"Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer\u2019s disease: systematic review and meta-analysis of observational studies. BMJ. 2003;327(7407):128.","journal-title":"BMJ."},{"issue":"10","key":"256_CR42","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-159-10-201311190-00007","volume":"159","author":"K Richardson","year":"2013","unstructured":"Richardson K, Schoen M, French B, Umscheid CA, Mitchell MD, Arnold SE, et al. Statins and cognitive function: a systematic review. Ann Intern Med. 2013;159(10):688\u201397.","journal-title":"Ann Intern Med."},{"issue":"2","key":"256_CR43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1447-0594.2009.00579.x","volume":"10","author":"W Muangpaisan","year":"2010","unstructured":"Muangpaisan W, Brayne C. Systematic review of statins for the prevention of vascular dementia or dementia. Geriatr Gerontol Int. 2010;10(2):199\u2013208.","journal-title":"Geriatr Gerontol Int."},{"key":"256_CR44","doi-asserted-by":"crossref","unstructured":"McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2009;2:CD003160.","DOI":"10.1002\/14651858.CD003160.pub2"},{"key":"256_CR45","doi-asserted-by":"crossref","unstructured":"Heneka MT, Fink A, Doblhammer G. Effect of pioglitazone medication on the incidence of dementia. Ann Neurol. doi: 10.1002\/ana.24439 (Epub 2015 May 14).","DOI":"10.1002\/ana.24439"},{"issue":"9","key":"256_CR46","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/archinte.163.9.1069","volume":"163","author":"C Tzourio","year":"2003","unstructured":"Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163(9):1069\u201375.","journal-title":"Arch Intern Med."},{"issue":"9137","key":"256_CR47","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(98)03086-4","volume":"352","author":"F Forette","year":"1998","unstructured":"Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352(9137):1347\u201351.","journal-title":"Lancet."},{"key":"256_CR48","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.brainres.2013.04.011","volume":"1514","author":"W Wharton","year":"2013","unstructured":"Wharton W, Gleason CE, Miller VM, Asthana S. Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS Cognitive and Affective sub study (KEEPS Cog). Brain Res. 2013;1514:12\u20137.","journal-title":"Brain Res."},{"key":"256_CR49","doi-asserted-by":"crossref","unstructured":"Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials. 2013;36(2):555\u201364.","DOI":"10.1016\/j.cct.2013.09.014"},{"issue":"1\u20132","key":"256_CR50","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jns.2009.02.352","volume":"283","author":"N Kandiah","year":"2009","unstructured":"Kandiah N, Feldman HH. Therapeutic potential of statins in Alzheimer\u2019s disease. J Neurol Sci. 2009;283(1\u20132):230\u20134.","journal-title":"J Neurol Sci."},{"issue":"2","key":"256_CR51","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/clpt.2012.222","volume":"93","author":"DG Crenshaw","year":"2013","unstructured":"Crenshaw DG, Gottschalk WK, Lutz MW, Grossman I, Saunders AM, Burke JR, et al. Using genetics to enable studies on the prevention of Alzheimer\u2019s disease. Clin Pharmacol Ther. 2013;93(2):177\u201385.","journal-title":"Clin Pharmacol Ther."},{"issue":"3","key":"256_CR52","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.nurt.2008.05.003","volume":"5","author":"G Landreth","year":"2008","unstructured":"Landreth G, Jiang Q, Mandrekar S, Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer\u2019s disease. Neurotherapeutics. 2008;5(3):481\u20139.","journal-title":"Neurotherapeutics."},{"key":"256_CR53","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fnagi.2010.00021","volume":"2","author":"N Nicolakakis","year":"2010","unstructured":"Nicolakakis N, Hamel E. The nuclear receptor PPARgamma as a therapeutic target for cerebrovascular and brain dysfunction in Alzheimer\u2019s disease. Front Aging Neurosci. 2010;2:21. doi: 10.3389\/fnagi.2010.00021 .","journal-title":"Front Aging Neurosci."},{"key":"256_CR54","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/epirev\/mxn010","volume":"30","author":"N Coley","year":"2008","unstructured":"Coley N, Andrieu S, Gardette V, Gillette-Guyonnet S, Sanz C, Vellas B, et al. Dementia prevention: methodological explanations for inconsistent results. Epidemiol Rev. 2008;30:35\u201366.","journal-title":"Epidemiol Rev."},{"issue":"21","key":"256_CR55","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1212\/01.wnl.0000260269.93245.d2","volume":"68","author":"CG Lyketsos","year":"2007","unstructured":"Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007;68(21):1800\u20138.","journal-title":"Neurology."},{"issue":"20","key":"256_CR56","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1001\/jama.289.20.2651","volume":"289","author":"SA Shumaker","year":"2003","unstructured":"Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women\u2019s Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289(20):2651\u201362.","journal-title":"JAMA."},{"issue":"18","key":"256_CR57","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1001\/jama.297.18.2018","volume":"297","author":"CL Campbell","year":"2007","unstructured":"Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA. 2007;297(18):2018\u201324.","journal-title":"JAMA."},{"issue":"10","key":"256_CR58","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1517\/13543784.2013.812631","volume":"22","author":"EL Ashby","year":"2013","unstructured":"Ashby EL, Kehoe PG. Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer\u2019s disease. Expert Opin Investig Drugs. 2013;22(10):1229\u201342.","journal-title":"Expert Opin Investig Drugs."},{"issue":"Suppl 2","key":"256_CR59","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.3233\/JAD-2012-111664","volume":"30","author":"WV Goodison","year":"2012","unstructured":"Goodison WV, Frisardi V, Kehoe PG. Calcium channel blockers and Alzheimer\u2019s disease: potential relevance in treatment strategies of metabolic syndrome. J Alzheimers Dis. 2012;30(Suppl 2):S269\u201382.","journal-title":"J Alzheimers Dis."},{"issue":"4","key":"256_CR60","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7(4):367\u201385.","journal-title":"Alzheimers Dement."},{"issue":"6279","key":"256_CR61","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1136\/bmj.282.6279.1847","volume":"282","author":"G Rose","year":"1981","unstructured":"Rose G. Strategy of prevention: lessons from cardiovascular disease. Br Med J (Clin Res Ed). 1981;282(6279):1847\u201351.","journal-title":"Br Med J (Clin Res Ed)."},{"issue":"6","key":"256_CR62","doi-asserted-by":"crossref","first-page":"e000833","DOI":"10.1136\/bmjopen-2012-000833","volume":"2","author":"BA Golomb","year":"2012","unstructured":"Golomb BA, Chan VT, Evans MA, Koperski S, White HL, Criqui MH. The older the better: are elderly study participants more non-representative? A cross-sectional analysis of clinical trial and observational study samples. BMJ Open. 2012;2(6):e000833. doi: 10.1136\/bmjopen-2012-000833 .","journal-title":"BMJ Open."},{"issue":"Suppl 1","key":"256_CR63","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.2105\/AJPH.2009.162982","volume":"100","author":"AP Herrera","year":"2010","unstructured":"Herrera AP, Snipes SA, King DW, Torres-Vigil I, Goldberg DS, Weinberg AD. Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. Am J Public Health. 2010;100(Suppl 1):S105\u201312.","journal-title":"Am J Public Health."},{"issue":"6","key":"256_CR64","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/sj.npp.1300690","volume":"30","author":"LJ Thal","year":"2005","unstructured":"Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005;30(6):1204\u201315.","journal-title":"Neuropsychopharmacology."},{"key":"256_CR65","doi-asserted-by":"crossref","first-page":"e3645","DOI":"10.1136\/bmj.e3645","volume":"344","author":"L Azoulay","year":"2012","unstructured":"Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ. 2012;344:e3645.","journal-title":"BMJ."},{"issue":"2","key":"256_CR66","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3233\/JAD-2009-0971","volume":"16","author":"S Andrieu","year":"2009","unstructured":"Andrieu S, Coley N, Aisen P, Carrillo MC, DeKosky S, Durga J, et al. Methodological issues in primary prevention trials for neurodegenerative dementia. J Alzheimers Dis. 2009;16(2):235\u201370.","journal-title":"J Alzheimers Dis."},{"issue":"9","key":"256_CR67","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1001\/jama.300.9.1027","volume":"300","author":"NT Lautenschlager","year":"2008","unstructured":"Lautenschlager NT, Cox KL, Flicker L, Foster JK, van Bockxmeer FM, Xiao J, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA. 2008;300(9):1027\u201337.","journal-title":"JAMA."},{"issue":"9984","key":"256_CR68","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","volume":"385","author":"T Ngandu","year":"2015","unstructured":"Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255\u201363.","journal-title":"Lancet."},{"issue":"23","key":"256_CR69","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.296.23.2805","volume":"296","author":"SL Willis","year":"2006","unstructured":"Willis SL, Tennstedt SL, Marsiske M, Ball K, Elias J, Koepke KM, et al. Long-term effects of cognitive training on everyday functional outcomes in older adults. JAMA. 2006;296(23):2805\u201314.","journal-title":"JAMA."},{"issue":"5","key":"256_CR70","doi-asserted-by":"crossref","first-page":"e61624","DOI":"10.1371\/journal.pone.0061624","volume":"8","author":"FD Wolinsky","year":"2013","unstructured":"Wolinsky FD, Vander Weg MW, Howren MB, Jones MP, Dotson MM. A randomized controlled trial of cognitive training using a visual speed of processing intervention in middle aged and older adults. PLoS One. 2013;8(5):e61624.","journal-title":"PLoS One."},{"issue":"6","key":"256_CR71","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jalz.2010.01.013","volume":"6","author":"K Yurko-Mauro","year":"2010","unstructured":"Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement. 2010;6(6):456\u201364.","journal-title":"Alzheimers Dement."},{"issue":"8","key":"256_CR72","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","volume":"71","author":"MC Donohue","year":"2014","unstructured":"Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, et al. The Preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71(8):961\u201370.","journal-title":"JAMA Neurol."},{"issue":"6","key":"256_CR73","doi-asserted-by":"crossref","first-page":"652","DOI":"10.4088\/JCP.13m08927","volume":"75","author":"N Ayutyanont","year":"2014","unstructured":"Ayutyanont N, Langbaum JB, Hendrix SB, Chen K, Fleisher AS, Friesenhahn M, et al. The Alzheimer\u2019s prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer\u2019s disease treatments in presenilin 1 E280A mutation carriers. J Clin Psychiatry. 2014;75(6):652\u201360.","journal-title":"J Clin Psychiatry."},{"issue":"6","key":"256_CR74","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jalz.2014.02.002","volume":"10","author":"JB Langbaum","year":"2014","unstructured":"Langbaum JB, Hendrix SB, Ayutyanont N, Chen K, Fleisher AS, Shah RC, et al. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer\u2019s disease. Alzheimers Dement. 2014;10(6):666\u201374.","journal-title":"Alzheimers Dement."},{"issue":"4","key":"256_CR75","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1001\/jamaneurol.2014.3375","volume":"72","author":"RE Amariglio","year":"2015","unstructured":"Amariglio RE, Donohue MC, Marshall GA, Rentz DM, Salmon DP, Ferris SH, et al. Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer\u2019s disease cooperative study cognitive function instrument. JAMA Neurol. 2015;72(4):446\u201354.","journal-title":"JAMA Neurol."},{"issue":"8","key":"256_CR76","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jamaneurol.2014.1120","volume":"71","author":"RJ Kryscio","year":"2014","unstructured":"Kryscio RJ. Secondary prevention trials in Alzheimer disease: the challenge of identifying a meaningful end point. JAMA Neurol. 2014;71(8):947\u20139.","journal-title":"JAMA Neurol."},{"issue":"4","key":"256_CR77","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.pneurobio.2010.11.005","volume":"95","author":"H Hampel","year":"2011","unstructured":"Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, et al. Biomarkers for Alzheimer\u2019s disease therapeutic trials. Prog Neurobiol. 2011;95(4):579\u201393.","journal-title":"Prog Neurobiol."},{"issue":"1","key":"256_CR78","first-page":"13","volume":"1","author":"B Vellas","year":"2014","unstructured":"Vellas B, Carrie I, Gillette-Guyonnet S, Touchon J, Dantoine T, Dartigues JF, et al. MAPT study: a multidomain approach for preventing Alzheimer\u2019s disease: design and baseline data. J Prev Alz Dis. 2014;1(1):13\u201322.","journal-title":"J Prev Alz Dis."},{"issue":"9","key":"256_CR79","doi-asserted-by":"crossref","first-page":"e12244","DOI":"10.1371\/journal.pone.0012244","volume":"5","author":"AD Smith","year":"2010","unstructured":"Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010;5(9):e12244.","journal-title":"PLoS One."},{"issue":"6","key":"256_CR80","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jalz.2012.09.012","volume":"9","author":"M Kivipelto","year":"2013","unstructured":"Kivipelto M, Solomon A, Ahtiluoto S, Ngandu T, Lehtisalo J, Antikainen R, et al. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): study design and progress. Alzheimers Dement. 2013;9(6):657\u201365.","journal-title":"Alzheimers Dement."},{"key":"256_CR81","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1749-6632.2009.04947.x","volume":"1180","author":"N Coley","year":"2009","unstructured":"Coley N, Andrieu S, Delrieu J, Voisin T, Vellas B. Biomarkers in Alzheimer\u2019s disease: not yet surrogate endpoints. Ann N Y Acad Sci. 2009;1180:119\u201324.","journal-title":"Ann N Y Acad Sci."},{"issue":"3","key":"256_CR82","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.neuron.2014.10.038","volume":"84","author":"R Sperling","year":"2014","unstructured":"Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer\u2019s disease: implications for prevention trials. Neuron. 2014;84(3):608\u201322.","journal-title":"Neuron."},{"issue":"8","key":"256_CR83","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1474-4422(08)70143-1","volume":"7","author":"R Peters","year":"2008","unstructured":"Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7(8):683\u20139.","journal-title":"Lancet Neurol."},{"issue":"26","key":"256_CR84","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1056\/NEJMoa054025","volume":"354","author":"JA McMahon","year":"2006","unstructured":"McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med. 2006;354(26):2764\u201372.","journal-title":"N Engl J Med."},{"issue":"1","key":"256_CR85","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nrneurol.2012.241","volume":"9","author":"RA Sperling","year":"2013","unstructured":"Sperling RA, Karlawish J, Johnson KA. Preclinical Alzheimer disease-the challenges ahead. Nat Rev Neurol. 2013;9(1):54\u20138.","journal-title":"Nat Rev Neurol."},{"issue":"3","key":"256_CR86","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):280\u201392.","journal-title":"Alzheimers Dement."},{"issue":"5123","key":"256_CR87","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science. 1993;261(5123):921\u20133.","journal-title":"Science."},{"issue":"1","key":"256_CR88","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1586\/14737175.2015.995168","volume":"15","author":"D Stephenson","year":"2015","unstructured":"Stephenson D, Perry D, Bens C, Bain LJ, Berry D, Krams M, et al. Charting a path toward combination therapy for Alzheimer\u2019s disease. Expert Rev Neurother. 2015;15(1):107\u201313.","journal-title":"Expert Rev Neurother."},{"issue":"1","key":"256_CR89","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/clpt.2009.68","volume":"86","author":"AD Barker","year":"2009","unstructured":"Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86(1):97\u2013100.","journal-title":"Clin Pharmacol Ther."},{"key":"256_CR90","volume-title":"Guidance for industry: adaptive design clinical trials for drugs and biologics. Draft guidance","author":"Food and Drug Administration","year":"2010","unstructured":"Food and Drug Administration. Guidance for industry: adaptive design clinical trials for drugs and biologics. Draft guidance. Maryland: FDA; 2010."},{"key":"256_CR91","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.exger.2014.05.002","volume":"57","author":"J Cedernaes","year":"2014","unstructured":"Cedernaes J, Schioth HB, Benedict C. Efficacy of antibody-based therapies to treat Alzheimer\u2019s disease: just a matter of timing? Exp Gerontol. 2014;57:104\u20136.","journal-title":"Exp Gerontol."},{"issue":"1","key":"256_CR92","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/ije\/14.1.32","volume":"14","author":"G Rose","year":"1985","unstructured":"Rose G. Sick individuals and sick populations. Int J Epidemiol. 1985;14(1):32\u20138.","journal-title":"Int J Epidemiol."},{"issue":"5","key":"256_CR93","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/archinternmed.2011.1391","volume":"172","author":"I Hajjar","year":"2012","unstructured":"Hajjar I, Hart M, Chen YL, Mack W, Milberg W, Chui H, et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Arch Intern Med. 2012;172(5):442\u20134.","journal-title":"Arch Intern Med."},{"issue":"24","key":"256_CR94","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.291.24.2947","volume":"291","author":"SA Shumaker","year":"2004","unstructured":"Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women\u2019s Health Initiative Memory Study. JAMA. 2004;291(24):2947\u201358.","journal-title":"JAMA."},{"issue":"7","key":"256_CR95","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.psyneuen.2009.02.009","volume":"34","author":"MC Tierney","year":"2009","unstructured":"Tierney MC, Oh P, Moineddin R, Greenblatt EM, Snow WG, Fisher RH, et al. A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women. Psychoneuroendocrinology. 2009;34(7):1065\u201374.","journal-title":"Psychoneuroendocrinology."},{"issue":"1","key":"256_CR96","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/WAD.0b013e3181611024","volume":"22","author":"T Gomez-Isla","year":"2008","unstructured":"Gomez-Isla T, Blesa R, Boada M, Clarimon J, Del Ser T, Domenech G, et al. A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer Dis Assoc Disord. 2008;22(1):21\u20139.","journal-title":"Alzheimer Dis Assoc Disord."},{"key":"256_CR97","unstructured":"University of Washington, Seattle Institute for Biomedical and Clinical Research, VA Puget Sound Health Care System. Effects of simvastatin on biomarkers (SimBio) [ClinicalTrials.gov identifier NCT01142336]. US National Institutes of Health, ClinicalTrials.gov. http:\/\/www.clinicaltrials.gov . Accessed 28 Jun 2015."},{"key":"256_CR98","unstructured":"Charite University, Berlin, Germany, German Federal Ministry of Education and Research. Trial of simvastatin in amnestic mild cognitive impairment (MCI) patients (SIMaMCI) [ClinicalTrials.gov identifier NCT00842920]. US National Institutes of Health, ClinicalTrials.gov. http:\/\/www.clinicaltrials.gov . Accessed 28 Jun 2015."},{"key":"256_CR99","unstructured":"University of Wisconsin\u2013Madison. Statin effects on beta-amyloid and cerebral perfusion in adults at risk for Alzheimer\u2019s disease (SHARP) [ClinicalTrials.gov identifier NCT00939822]. US National Institutes of Health, ClinicalTrials.gov. http:\/\/www.clinicaltrials.gov . Accessed 28 Jun 2015."},{"key":"256_CR100","unstructured":"Banner Alzheimer\u2019s Institute. Alzheimer\u2019s Prevention Initiative. http:\/\/banneralz.org\/research-plus-discovery\/alzheimers-prevention-initiative.aspx . Accessed 1 July 2015."},{"key":"256_CR101","unstructured":"Eisai Inc. A study to evaluate safety, tolerability, and efficacy of BAN2401 in subjects with early Alzheimer\u2019s disease [ClinicalTrials.gov identifier NCT01767311]. US National Institutes of Health, ClinicalTrials.gov. http:\/\/www.clinicaltrials.gov . Accessed 28 Jun 2015."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-015-0256-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-015-0256-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-015-0256-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T02:10:56Z","timestamp":1717985456000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-015-0256-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":101,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["256"],"URL":"https:\/\/doi.org\/10.1007\/s40263-015-0256-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}